Get the Stockscreener App
5.99
2.78%
-0.18
Recursion Pharmaceuticals Inc stock is traded at $5.99, with a volume of 4.38M.
It is down -2.78% in the last 24 hours and down -29.43% over the past month.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
See More
Previous Close:
$6.17
Open:
$6.17
24h Volume:
4.38M
Relative Volume:
0.20
Market Cap:
$2.41B
Revenue:
$64.60M
Net Income/Loss:
$-377.75M
P/E Ratio:
-3.8645
EPS:
-1.55
Net Cash Flow:
$-335.64M
1W Performance:
-3.88%
1M Performance:
-29.43%
6M Performance:
-8.70%
1Y Performance:
-45.37%
1-Day Range:
$5.96
$6.2575
1-Week Range:
$5.73
$6.642
52-Week Range:
$5.60
$12.36
Recursion Pharmaceuticals Inc Stock (RXRX) Company Profile
Name
Recursion Pharmaceuticals Inc
Sector
Industry
Phone
(385) 269-0203
Address
41S RIO GRANDE STREET, SALT LAKE CITY
Compare RXRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RXRX
Recursion Pharmaceuticals Inc
|
5.975 | 2.41B | 64.60M | -377.75M | -335.64M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.67 | 130.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.25 | 75.53B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
578.35 | 35.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.87 | 31.72B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.74 | 26.76B | 3.32B | -860.46M | -1.04B | -8.32 |
Recursion Pharmaceuticals Inc Stock (RXRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-22-23 | Initiated | Morgan Stanley | Equal-Weight |
| Mar-16-23 | Initiated | Needham | Buy |
| Sep-16-22 | Initiated | KeyBanc Capital Markets | Overweight |
| Apr-18-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-04-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-21-21 | Initiated | Berenberg | Buy |
| May-11-21 | Initiated | BofA Securities | Buy |
| May-11-21 | Initiated | Goldman | Neutral |
| May-11-21 | Initiated | JP Morgan | Neutral |
| May-11-21 | Initiated | KeyBanc Capital Markets | Overweight |
| May-11-21 | Initiated | SVB Leerink | Outperform |
View All
Recursion Pharmaceuticals Inc Stock (RXRX) Latest News
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought - AOL
Proficio Capital Partners LLC Makes New $163,000 Investment in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - Defense World
Recursion Pharmaceuticals: Stretched Thin And Chasing Unicorns - Seeking Alpha
Jim Cramer on Recursion Pharmaceuticals, Inc. (RXRX): ‘We’re Going To Have To Hold Off’ - Insider Monkey
Recursion Pharma Gets A Price-Target Cut After Q4 Miss: Retail Bearish Even As Cathie Wood's Ark Buys The Dip - MSN
Why Recursion Pharmaceuticals Stock Is Sinking Today - Yahoo Finance
Jim Cramer’s Latest Lightning Round: 8 Stocks in Focus - Insider Monkey
Is This Beaten-Down Artificial Intelligence (AI) Stock a Buy? - Nasdaq
Cathie Wood-Led Ark Invest Roblox, Roku, UiPath As Markets Take A Dip - Benzinga
QRG Capital Management Inc. Grows Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - Defense World
This Is What Whales Are Betting On Recursion Pharmaceuticals - Benzinga
Private Advisor Group LLC Increases Stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - Defense World
4 Things You Need to Know if You Buy Recursion Pharmaceuticals Stock Today - MSN
This Biotech Stock Could Be the Best Investment of the Decade - The Globe and Mail
April 25th Options Now Available For Recursion Pharmaceuticals (RXRX) - Nasdaq
Down Over 40%, Is Recursion Pharmaceuticals a Buy on the Dip? - MSN
IFP Advisors Inc Acquires 7,455 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - Defense World
Recursion Pharmaceuticals (RXRX) Remains Optimistic Despite Q4 Disappointment - TipRanks
TechBio Latest News - substack.com
How To Trade (RXRX) - Stock Traders Daily
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q4 2024 Earnings Call Transcript - MSN
News Flash: Analysts Just Made A Sizeable Upgrade To Their Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Forecasts - Yahoo Finance
Recursion Pharmaceuticals Shares Dip Amid Revenue Timing - TipRanks
Why Recursion Pharmaceuticals, Inc. (RXRX) Crashed on Monday - MSN
Rhumbline Advisers Has $2.26 Million Stock Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - Defense World
Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 5.3% on Disappointing Earnings - Defense World
Recursion Pharmaceuticals Inc (RXRX) Q4 2024 Earnings Call Highlights: Strong Financial ... By GuruFocus - Investing.com Canada
Recursion Pharmaceuticals projects $100M synergies in 2025 amid advancing pipeline and partnerships - MSN
Recursion Pharmaceuticals’ Earnings Call Highlights Growth - TipRanks
Recursion Pharmaceuticals (NasdaqGS:RXRX) Surges 6% Following US$500 Million Follow-On Equity Offering - Yahoo Finance
Recursion Pharmaceuticals' Update Could Shed Light On Pipeline, Cost-Saving Plans, Analyst Says - Benzinga India
Atria Wealth Solutions Inc. Invests $75,000 in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - Defense World
This Just In: Analysts Are Boosting Their Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Outlook for This Year - Simply Wall St
Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap Down After Earnings Miss - Defense World
Recursion Pharmaceuticals Stock Scores RS Ratings Over 90 - MSN
AI Drug Firm Recursion Wants to Be the Amazon Prime of Pharma - Advisor Perspectives
Cathie Wood's Ark Invest Loads Up On Tempus AI, Archer Aviation, But Sells Twist Bioscience: Here Are Key Ark Trades This FridayArcher Aviation (NYSE:ACHR), Accolade (NASDAQ:ACCD) - Benzinga
Recursion stock holds as Cowen sees merger synergies By Investing.com - Investing.com Canada
Recursion Pharmaceuticals Reports Mixed 2024 Financial Results - TipRanks
Cathie Wood’s ARK ETF bolsters Tempus AI, Recursion stocks By Investing.com - Investing.com Australia
Cathie Wood's ARK ETF bolsters Tempus AI, Recursion stocks - Investing.com
Cathie Wood’s ARK ETF bolsters Tempus AI, Recursion stocks - Investing.com India
Strong Buy Recommendation for Recursion Pharmaceuticals: Leading Techbio Innovator with Robust Financials and Strategic AI Integration - TipRanks
Best Biotech Stocks To Keep An Eye OnFebruary 28th - MarketBeat
Recursion Pharmaceuticals (RXRX) Reports Q4 Loss, Lags Revenue Estimates - MSN
Recursion Pharmaceuticals misses Q4 estimates, shares dip By Investing.com - Investing.com Australia
Recursion Pharmaceuticals misses Q4 estimates, shares dip - Investing.com
Recursion Pharmaceuticals, DoubleVerify Holdings, Praxis Precision Medicines - TradingView
Recursion Pharmaceuticals Inc Stock (RXRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Recursion Pharmaceuticals Inc Stock (RXRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Gibson Christopher | Chief Executive Officer |
Mar 06 '25 |
Sale |
6.37 |
20,000 |
127,400 |
1,256,024 |
5.68%
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):